| Literature DB >> 33370241 |
Nicholas M Barnes1, Gerard P Ahern2, Carine Becamel2, Joël Bockaert2, Michael Camilleri2, Severine Chaumont-Dubel2, Sylvie Claeysen2, Kathryn A Cunningham2, Kevin C Fone2, Michael Gershon2, Giuseppe Di Giovanni2, Nathalie M Goodfellow2, Adam L Halberstadt2, Rachel M Hartley2, Ghérici Hassaine2, Katharine Herrick-Davis2, Ruud Hovius2, Enza Lacivita2, Evelyn K Lambe2, Marcello Leopoldo2, Finn Olav Levy2, Sarah C R Lummis2, Philippe Marin2, Luc Maroteaux2, Andrew C McCreary2, David L Nelson2, John F Neumaier2, Adrian Newman-Tancredi2, Hugues Nury2, Alexander Roberts2, Bryan L Roth2, Anne Roumier2, Gareth J Sanger2, Milt Teitler2, Trevor Sharp2, Carlos M Villalón2, Horst Vogel2, Stephanie W Watts2, Daniel Hoyer2.
Abstract
5-HT receptors expressed throughout the human body are targets for established therapeutics and various drugs in development. Their diversity of structure and function reflects the important role 5-HT receptors play in physiologic and pathophysiological processes. The present review offers a framework for the official receptor nomenclature and a detailed understanding of each of the 14 5-HT receptor subtypes, their roles in the systems of the body, and, where appropriate, the (potential) utility of therapeutics targeting these receptors. SIGNIFICANCE STATEMENT: This review provides a comprehensive account of the classification and function of 5-hydroxytryptamine receptors, including how they are targeted for therapeutic benefit.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33370241 PMCID： PMC7770494 DOI： 10.1124/pr.118.015552
Source DB: PubMed Journal: Pharmacol Rev ISSN： 0031-6997 Impact factor: 25.468